ArticleFrontiers in immunology2019
Adeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming.
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- A viral-vectored multipathogen vaccine platform based on replication-competent vaccinia virus and adeno-associated virus.Frontiers in immunology · 2026Article
- Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- The Application of DNA Viruses to Biotechnology.Viruses · 2025Review
- Recent Advances in Designing Adeno-Associated Virus-Based Vaccines Against Viral Infections.Pharmaceutics · 2024Review
- Article
- A Novel Ex Vivo Assay to Evaluate Functional Effectiveness of Plasmodium vivax Transmission-Blocking Vaccine Using Pvs25 Transgenic Plasmodium berghei.The Journal of infectious diseases · 2024Article
- Article
- Review
- Resistance towards ChadOx1 nCoV-19 in an 83 Years Old Woman Experiencing Vaccine Induced Thrombosis with Thrombocytopenia Syndrome.Vaccines · 2022Article
- Efforts to Develop Pfs25 Vaccines.The American journal of tropical medicine and hygiene · 2022Article
- Article
- Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Review
- Article
- Sterile protection and transmission blockade by a multistage anti-malarial vaccine in the pre-clinical study.Frontiers in immunology · 2022Article
- Advancements in protein nanoparticle vaccine platforms to combat infectious disease.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019.Advanced nanobiomed research · 2021Article
- Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?Frontiers in immunology · 2021Review
- Liver-Directed AAV8 Booster Vaccine ExpressingFrontiers in immunology · 2021Article
- Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.ACS biomaterials science & engineering · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An ideal malaria vaccine platform should potently induce protective immune responses and block parasite transmission from mosquito to human, and it should maintain these effects for an extended period. Here, we have focused on vaccine development based on adeno-associated virus serotype 1 (AAV1), a viral vector widely studied in the field of clinical gene therapy that is able to induce long-term transgene expression without causing toxicity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.